Journal article
EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC
Journal of oncology pharmacy practice, Vol.18(2), pp.245-249
06/2012
DOI: 10.1177/1078155211408373
PMID: 21733906
Abstract
Purpose: The purpose of this review article is to describe the recent data supporting the use of epidermal growth factor receptor (EGFR) receptor tyrosine kinase inhibitors (TKIs) in the first-line setting of EGFR mutation-positive non-small cell lung cancer (NSCLC).
Summary: EGFR receptor TKIs were originally developed in unselected NSCLC patients and demonstrated modest clinical benefit compared to placebo. With the discovery of improved benefits in the approximately 16% of NSCLC patients with an EGFR mutation, trials in selected populations were undertaken, demonstrating comparable efficacy to standard chemotherapy with an improved toxicity profile. The most common toxicity is rash, sometimes requiring dose adjustment and discontinuation and the most serious toxicity is interstitial lung disease, which occurs in about 1% of patients treated with EGFR receptor TKIs and is fatal in 30% who develop this toxicity.
Conclusion: The EGFR receptor TKIs are an effective therapy in EGFR-mutated NSCLC and are recommended as first-line therapy for those with advanced or metastatic disease.
Details
- Title: Subtitle
- EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC
- Creators
- Kimberly J Gorden - University of Wisconsin–MadisonParvin Mesbah - University of Wisconsin–MadisonJill M Kolesar - University of Wisconsin Carbone Cancer Center
- Resource Type
- Journal article
- Publication Details
- Journal of oncology pharmacy practice, Vol.18(2), pp.245-249
- DOI
- 10.1177/1078155211408373
- PMID
- 21733906
- ISSN
- 1078-1552
- eISSN
- 1477-092X
- Language
- English
- Date published
- 06/2012
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695796302771
Metrics
2 Record Views